"The U.S. Food and Drug Administration today approved the Argus II Retinal Prosthesis System, the first implanted device to treat adult patients with advanced retinitis pigmentosa (RP). The device, which includes a small video camera, transmitter "...
LACRISERT (cellulose) ®
(hydroxypropyl cellulose ophthalmic insert)
Note: Your licensed practitioner or a trained associate can demonstrate the proper use of LACRISERT (cellulose) *. Please read and follow these instructions carefully for your subsequent use.
Clinical experience with LACRISERT (cellulose) indicates that in some patients several weeks may be required before satisfactory improvement of symptoms is achieved.
Two applicators (one spare) are supplied with each package.
Before opening the package of LACRISERT (cellulose) , wash your hands thoroughly with soap and water.
STEP 1: On a flat surface, open blister pocket slowly and smoothly by peeling back label area. Each blister pocket contains one LACRISERT (cellulose) ophthalmic insert.
STEP 2: Open applicator package with label side up. Avoid touching grooved tip of the applicator. Pick up applicator by the wide end and rinse the tip thoroughly under hot running tap water. Gently shake off excess water.
STEP 3: Hold applicator with tip facing down and with forefinger on top to guide and apply gentle pressure. Lightly press the grooved tip of the applicator onto the LACRISERT (cellulose) ophthalmic insert and it will adhere to the applicator.
It is important to follow STEPS 4 and 5 carefully or you might experience difficulty in keeping LACRISERT (hydroxypropyl cellulose ophthalmic insert) in your eye.
STEP 4: Look into a mirror. Starting with the right eye, turn your head to the right so that the colored part of the eye is close to your nose. Use your free hand to grasp the lower lid between the thumb and index finger. Pull the lid away from the eyeball and create a pocket between the white part of the eyeball and the lid.
STEP 5: Place the tip of the applicator containing LACRISERT (cellulose) into the pocket. Avoid touching the colored part of the eye.
Remove the applicator. It is important, after removing the applicator, to look down, then release the lower eyelid. LACRISERT (hydroxypropyl cellulose ophthalmic insert) should remain deep in the lower pocket recess of the eye and not near the lower eyelid.
Repeat procedure with left eye, turning head to the left so that the colored part of the eye is close to your nose.
Rinse the applicator thoroughly under hot running tap water after use. Gently shake off visible water droplets and promptly return it to the storage container. Note that the storage container provides space for a strip of two LACRISERT (cellulose) ophthalmic inserts next to the applicator storage compartment.
If LACRISERT (cellulose) causes worsening of symptoms, or if new symptoms develop, it should be removed and your prescriber contacted.
Should the removal of the LACRISERT (cellulose) ophthalmic insert be necessary, follow these instructions.
- Locate LACRISERT (cellulose) by pulling the lid away from the eyeball while looking for LACRISERT (cellulose) in a mirror.
- Then close the eyelids.
- When located, move LACRISERT (cellulose) upward with your fingers through the closed eyelids.
- Keep the lids against the eyeball and LACRISERT (cellulose) should slip over the lid margin so that you can remove it with a clean facial tissue without touching the colored part of the eye.
CAUTION: Because this product may produce transient blurring of vision, you should exercise caution when operating hazardous machinery or driving a motor vehicle.
Store below 30°C (86°F).
Last reviewed on RxList: 3/13/2008
This monograph has been modified to include the generic and brand name in many instances.
Additional Lacrisert Information
Lacrisert - User Reviews
Lacrisert User Reviews
Now you can gain knowledge and insight about a drug treatment with Patient Discussions.
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Get breaking medical news.